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Background
Malaria during pregnancy, especially Plasmodium falci-
parum malaria, is linked to increased morbidity and mor-
tality, which must be reduced by preventive measures
and effective case management [1-3]. The World Health
Organization (WHO) recommends artemisinin-based
combination therapy (ACT) to treat uncomplicated
P. falciparum malaria during the second and third trime-
sters of pregnancy, and quinine plus clindamycin during
the first trimester [4]. However, the national policies of
many African countries currently recommend quinine
throughout pregnancy. Therefore, the objective is to pro-
vide a summary of available data on the safety and effi-
cacy of artemether-lumefantrine (AL) in pregnancy.
Materials and methods
A systematic English-language research identified 16 publi-
cations from 1989 to October 2011 with reports of arte-
mether or AL exposure in pregnancy, including randomized
clinical trials, observational studies, and systematic reviews.
Results
Overall, there were 1,103 reports of AL use in pregnant
women: 890 second/third trimester exposures; 212 first
trimester exposures; and 1 case where the trimester of
exposure was not reported. In the second and third trime-
sters, AL was not associated with increased adverse preg-
nancy outcomes compared with quinine or sulphadoxine-
pyrimethamine, showed improved tolerability relative to
quinine, and its efficacy was non-inferior to quinine.
Although, few reports suggest that the pharmacokinetics
of anti-malarial drugs may change in pregnancy, the
majority of studies reported high cure rates and adequate
tolerability. As there are fewer reports of AL safety in
the first trimester, additional data are required to assess
the potential to use AL in the first trimester.
Conclusions
These findings reinforce the WHO recommendation to
treat uncomplicated P. falciparum malaria with quinine
plus clindamycin in early pregnancy and ACT in later
pregnancy.
Author details
1Public Health Department, Tropical Diseases Research Centre,
P.O. Box 71769, Ndola, Zambia. 2Malaria Research and Training Centre,
University of Bamako, P.O. Box 1805, Bamako, Mali. 3Medical Research
Council Unit, P.O. Box273, Fajara, The Gambia. 4Department of Pediatrics,
College of Medicine, University of Nigeria, P.O. Box 3295, Enugu, Nigeria.
5Kenya Medical Research Institute, P.O. Box 54, Kisumu, Kenya.
6Novartis Pharmaceuticals Corporation, East Hanover, NJ07936-1080, USA.
Published: 15 October 2012
References
1. Whitty CJ, Edmonds S, Mutabingwa TK: Malaria in pregnancy. BJOG 2005,
112:1189-1195.
2. van Geertruyden JP, Thomas F, Erhart A, D’Alessandro U: The contribution
of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg 2004,
71:35-40.
3. Menendez C, Romagosa C, Ismail MR, Carrilho C, Saute F, Osman N,
Machungo F, Bardaji A, Quinto L, Mayor A, Naniche D, Dobaño C, Alonso PL,
Ordi J: An autopsy study of maternal mortality in Mozambique: the
contribution of infectious diseases. PLoS Med 2008, 5:e44.
4. Guidelines for the Treatment of Malaria. World Health Organization, 2 2010.
doi:10.1186/1475-2875-11-S1-O39
Cite this article as: Manyando et al.: Safety and efficacy of artemether-
lumefantrine against uncomplicated Plasmodium falciparum malaria
during pregnancy: a systematic review. Malaria Journal 2012 11(Suppl 1):
O39.
1Public Health Department, Tropical Diseases Research Centre,
P.O. Box 71769, Ndola, Zambia
Full list of author information is available at the end of the article
Manyando et al. Malaria Journal 2012, 11(Suppl 1):O39
http://www.malariajournal.com/content/11/S1/O39
© 2012 Manyando et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
